L-Vac Adjuvant Technology
We use our proprietary liposomal nanoparticle technology to make vaccines. This platform technology is called L-Vac. L-Vac consist of natural lipids and FDA approved excipients that together can be processed to create an immune stimulating particulate delivery system that is compatible with different types of antigen.
L-Vac is a novel adjuvant (immunostimulant) and enhances immune response against protein antigens.
L-Vac enhanced immune response in animals against the spike proteins of SARS-CoV-2 and against tetanus toxoid by 7-folds and 27-fold respectively, suggesting that the antigen dose can be reduced remarkably if it is combined with L-Vac.
L-Vac protects the protein against degradation and enhances its stability. When L-Vac is incorporated into the vaccine design early on the resulting vaccine can be freeze-dried and be distributed at room temperature.
L-Vac can be customized for use with different antigens. It can also be supplied as a ready to use liposome for R&D or for development of vaccines.